Skip to main content
TipRanks
Go Ultimate75% OFF

Hoshi Iryosanki Co., Ltd. (7634) AI Stock Analysis

0 Followers
JP:7634

Hoshi Iryosanki Co., Ltd.

(TSE/TYO:7634)

Select Model
Rating:82.1Outperform
Price Target:JPY 6,116.00â–²(27.82% Upside)
Action:reiterated
Date:08/19/26

The overall score reflects a financially sound, low-leverage healthcare company with reliable cash flow and healthy margins as the primary strength, supported by a constructive technical trend and reasonably attractive valuation, while recent margin and earnings softness remain key factors to monitor.

Positive Factors
Steady Revenue and Operating ProfitabilityThe company has expanded its revenue base while preserving solid operating profitability. This combination indicates an established distribution franchise and suggests that its healthcare-provider relationships can support durable earnings over the next several quarters.
Negative Factors
Moderate Revenue Growth PaceAlthough revenue has grown over time, the reported growth rate is modest. A slower expansion pace may limit operating leverage and make future earnings increasingly dependent on margin management, product mix, or gains in the domestic healthcare market.

Hoshi Iryosanki Co., Ltd. (7634) vs. iShares MSCI Japan ETF (EWJ)

-5%0%5%10%15%20%25%30%JP:7634+3.16%EWJ+16.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 14.95B
Dividend Yield
1.99%
Average Volume (3M)
615
Price to Earnings (P/E)
10.5
Beta (1Y)
0.10
Revenue Growth
5.25%
EPS Growth
-2.63%
Country
Japan
Employees
527
Sector
Healthcare
Sector Strength
51
Industry
Medical - Care Facilities

Hoshi Iryosanki Co., Ltd. Business Overview & Revenue Model

Company Description

Hoshi Iryo-Sanki Co., Ltd., a Japanese firm, specializes in the production and distribution of pharmaceutical-grade medical oxygen and nitrous oxide. Its business activities are structured across five distinct divisions: Medical Gas, Home Healthcare,...

How the Company Makes Money

The company primarily makes money by selling and distributing medical devices and healthcare-related products to medical institutions in Japan. Revenue is generated mainly from (1) product sales (i.e., wholesaling/distribution margins earned between...

Hoshi Iryosanki Co., Ltd. Financial Statement Overview

Summary

Revenue and margins are solid and supported by strong cash generation, but recent profit softness, margin compression, and declining return on equity temper the strength.

Income Statement

74Positive

Balance Sheet

88Very Positive

Cash Flow

82Very Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue15.99B15.52B15.10B14.78B13.78B12.77B
Gross Profit7.85B7.39B7.31B6.96B6.51B6.03B
EBITDA3.08B2.87B2.81B2.86B2.71B2.48B
Net Income1.43B1.37B1.46B1.40B1.25B1.11B
Balance Sheet
Total Assets26.93B26.74B24.59B23.04B21.25B20.25B
Cash, Cash Equivalents and Short-Term Investments11.29B11.21B10.63B9.76B9.03B8.76B
Total Debt01.28B1.09B834.44M1.00B1.29B
Total Liabilities6.14B6.42B5.87B5.66B5.66B5.74B
Stockholders Equity20.48B20.01B18.43B17.10B15.37B14.29B
Cash Flow
Free Cash Flow02.16B1.65B2.15B1.89B1.40B
Operating Cash Flow02.48B2.19B2.40B2.29B1.97B
Investing Cash Flow0-1.54B-5.28B-744.85M-1.06B-690.26M
Financing Cash Flow0-948.38M-739.64M-902.90M-957.69M-936.90M

Hoshi Iryosanki Co., Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price4785.00

Price Trends

50DMA5036.64Negative
100DMA5045.20Negative
200DMA5066.32Negative

Market Momentum

MACD-82.51Positive
RSI31.37Neutral
STOCH7.88Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7634, the sentiment is Negative. The current price of 4785.00 is below the 20-day moving average (MA) of 4915.25, below the 50-day MA of 5036.64, and below the 200-day MA of 5066.32, indicating a bearish trend. The MACD of -82.51 indicates Positive momentum. The RSI at 31.37 is Neutral, neither overbought nor oversold. The STOCH value of 7.88 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7634.

Hoshi Iryosanki Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:7634 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:7634JP:763482OutperformJPY 14.78B10.48―1.99%5.25%-2.63%
JP:6678JP:667882OutperformJPY 18.47B12.39―5.95%17.11%23.02%
JP:7707JP:770762NeutralJPY 5.31B13.32―1.04%9.27%―
JP:4350JP:435060NeutralJPY 15.75B17.57―2.30%6.89%-55.21%
JP:7743JP:774354NeutralJPY 23.79B21.83―1.91%4.13%-39.39%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:7600JP:760045NeutralJPY 8.43B-5.42―5.31%-8.68%-75.03%

* Healthcare Sector Average

Performance Comparison

0%50%100%JP:7634JP:4350JP:6678JP:7600JP:7707JP:7743Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:7634 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:7634Hoshi Iryosanki Co., Ltd.4785.00102.362.19%
JP:4350Medical System Network Co., Ltd.522.0037.097.65%
JP:6678Techno Medica Co., Ltd.2167.00284.9515.14%
JP:7600Japan Medical Dynamic Marketing, Inc.320.00-162.41-33.67%
JP:7707Precision System Science Co.,Ltd192.00-12.00-5.88%
JP:7743Seed Co., Ltd.786.00231.6341.78%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 17, 2026